KEGG   DISEASE: InsomniaHelp
Entry
H01609                      Disease                                

Name
Insomnia
Description
Insomnia is a common disorder with a prevalence of about 10% in the general population. The most common complaints related to insomnia are difficulty initiating sleep (sleep-onset insomnia), difficulty maintaining sleep due to prolonged nocturnal awakenings (sleep-maintenance insomnia), early morning awakenings, and excessive daytime sleepiness resulting from lack of sleep. Furthermore, insomnia is associated with an increased risk of anxiety and depression, suicidality, and cardiovascular diseases. Currently, cognitive behavioral therapy for insomnia (CBT-I) is recommended as first-line therapy. While behavioral therapies are effective for chronic insomnia in some patients, pharmacotherapy is frequently used when immediate short-term symptom relief is needed. The most effective pharmacologic therapies for insomnia are benzodiazepines, benzodiazepine-receptor agonists, melatonin-receptor agonists, and antidepressants.
Category
Nervous system disease
Brite
Human diseases [BR:br08402]
 Nervous system diseases
  Other nervous and sensory system diseases
   H01609  Insomnia
Human diseases in ICD-11 classification [BR:br08403]
 07 Sleep-wake disorders
  Insomnia disorders
   7A00  Chronic insomnia
    H01609  Insomnia
   7A01  Short-term insomnia
    H01609  Insomnia
BRITE hierarchy
Drug
Diphenhydramine hydrochloride [DR:D00669]
Doxepin hydrochloride [DR:D00814]
Phenobarbital sodium [DR:D00701]
Secobarbital sodium [DR:D01310]
Estazolam [DR:D00311]
Triazolam [DR:D00387]
Quazepam [DR:D00457]
Zolpidem tartrate [DR:D00706]
Eszopiclone [DR:D02624]
Ramelteon [DR:D02689]
Suvorexant [DR:D10082]
Other DBs
ICD-11: 7A00 7A01
ICD-10: F51.0 G47.0
MeSH: D007319
Reference
  Authors
Lancee J, van Straten A, Morina N, Kaldo V, Kamphuis JH
  Title
Guided Online or Face-to-Face Cognitive Behavioral Treatment for Insomnia: A Randomized Wait-List Controlled Trial.
  Journal
Sleep 39:183-91 (2016)
DOI:10.5665/sleep.5344
Reference
  Authors
Palagini L, Faraguna U, Mauri M, Gronchi A, Morin CM, Riemann D
  Title
Association between stress-related sleep reactivity and cognitive processes in insomnia disorder and insomnia subgroups: preliminary results.
  Journal
Sleep Med 19:101-7 (2016)
DOI:10.1016/j.sleep.2015.10.020
Reference
PMID:16750462 (drug)
  Authors
Najib J
  Title
Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia.
  Journal
Clin Ther 28:491-516 (2006)
DOI:10.1016/j.clinthera.2006.04.014
Reference
PMID:27253658 (drug)
  Authors
Schoedel KA, Sun H, Sellers EM, Faulknor J, Levy-Cooperman N, Li X, Kennedy WP, Cha JH, Lewis NM, Liu W, Bondiskey P, McCrea JB, Panebianco DL, Troyer MD, Wagner JA
  Title
Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
  Journal
J Clin Psychopharmacol 36:314-23 (2016)
DOI:10.1097/JCP.0000000000000516
Reference
PMID:26438969 (drug)
  Authors
Cardinali DP, Golombek DA, Rosenstein RE, Brusco LI, Vigo DE
  Title
Assessing the efficacy of melatonin to curtail benzodiazepine/Z drug abuse.
  Journal
Pharmacol Res 109:12-23 (2016)
DOI:10.1016/j.phrs.2015.08.016
Reference
PMID:18463341 (drug)
  Authors
Passarella S, Duong MT
  Title
Diagnosis and treatment of insomnia.
  Journal
Am J Health Syst Pharm 65:927-34 (2008)
DOI:10.2146/ajhp060640
Reference
PMID:26940892 (drug)
  Authors
Morin CM, Edinger JD, Krystal AD, Buysse DJ, Beaulieu-Bonneau S, Ivers H
  Title
Sequential psychological and pharmacological therapies for comorbid and primary insomnia: study protocol for a randomized controlled trial.
  Journal
Trials 17:118 (2016)
DOI:10.1186/s13063-016-1242-3
LinkDB All DBs

» Japanese version

DBGET integrated database retrieval system